STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth Conference

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses, announces its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. Patrick F. Williams, Chief Financial Officer, will engage in a fireside chat on August 13, 2024, at 8:30 a.m. Eastern Time. Investors and the public can access a live webcast of the event through STAAR's investor website.

STAAR Surgical, with over 40 years of focus on ophthalmic surgery, specializes in implantable lenses for visual freedom. Their EVO ICL™ product line has sold more than 3,000,000 ICLs globally, marketed in over 75 countries. The company operates facilities in California and Switzerland, continuing its commitment to innovative eye care solutions.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Canaccord Genuity 44th Annual Growth Conference, which will be held in Boston, Massachusetts.

Patrick F. Williams, Chief Financial Officer, will participate in a fireside chat on Tuesday, August 13, 2024, at 8:30 a.m. Eastern Time. A live webcast, including an option to pre-register, can be accessed at https://investors.staar.com/ or directly here. An archive of the webcast will also be available on STAAR’s investor website following the conference.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730909191/en/

Investors & Media

Brian Moore

Vice President, Investor Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When is STAAR Surgical (STAA) participating in the Canaccord Genuity Growth Conference?

STAAR Surgical (STAA) is participating in the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, with a fireside chat scheduled at 8:30 a.m. Eastern Time.

Who will represent STAAR Surgical (STAA) at the Canaccord Genuity conference?

Patrick F. Williams, Chief Financial Officer of STAAR Surgical, will represent the company at the Canaccord Genuity conference.

How many ICLs has STAAR Surgical (STAA) sold to date?

STAAR Surgical (STAA) has sold more than 3,000,000 Implantable Collamer® Lenses (ICLs) to date.

In how many countries does STAAR Surgical (STAA) market its ICL products?

STAAR Surgical (STAA) markets its Implantable Collamer® Lenses (ICLs) in over 75 countries.

What is the main product line of STAAR Surgical (STAA)?

The main product line of STAAR Surgical (STAA) is the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia.